Professional Documents
Culture Documents
The Standard 2012 Winter
The Standard 2012 Winter
In this Issue
CEO Column
2 Message from the CEO Solving USPs Riddle of the Sphinx
USP Science
4 5 In Pursuit of Modern, Comprehensive Compendia Proposed General Chapter Addresses Subvisible Particulate Matter in Therapeutic Protein Injections USP Identification Tests to Be Modernized
More...
International
9 Global Public Health View, Flexible Standards-Setting Approach Drive New Compendium
10 USP Collaborates with FDA, IPC on India Courses 11 Global Quality Standards for Biologics and Supply Chain Management the Focus of Mumbai Meeting 12 First Global Summit of Pharmacopeias Hosted in Beijing
More...
USP CEO Roger L. Williams is welcomed to Ghana. USP expects a new center located in the country to open in 2013.
PQM Program
15 PQM Assists Ethiopia in Achieving International Laboratory Accreditation
More...
Inside USP
16 Global Philanthropic Health Initiatives Strengthened with New USP Vice President of Development
More...
Q U A L I T Y S TA N DA R D S f o r M e d i c i n e s , D i e t a r y S u p p l e m e n t s , a n d F o o d I n g r e d i e n t s W O R L DW I D E
USP Headquarters Maryland, USA Europe/Middle East/Africa Basel, Switzerland USPIndia Private Ltd. Hyderabad, India USPChina Shanghai, China USPBrazil So Paulo, Brazil
In this Issue
USP Science
6 7
Continued
USP Proposes New Standards for Orally and Nasally Inhaled Medicines Adulteration of Foods and Dietary Supplements Workshop Examines Current Vulnerabilities, the Role of Standards Critical Quality Considerations for Probiotics and Other Microbial Food Cultures Offered in New Draft FCC Standards
International
13 International Exchange Furthered with USP Japan Trip 13 Chile and USP Strengthen Ties, Commitment to Quality Medicines
PQM Program
15 PQM Establishes Medicines Quality Monitoring in Yunnan, China
Inside USP
16 USP Launches New Website
I am at times dismayed by the arguments people give on why there should not be a good public monograph with allied reference materials for all drugs moving in commerce.
Roger L. Williams, Chief Executive Officer, USP
Turning then to drugs, I start with the somber observation that I am at times dismayed by the arguments people give on why there should not be a good public monograph with allied reference materials for all drugs moving in commerce. These range from the presence of manufacturers proprietary in-house quality standards (particularly when there is only one manufacturer in a market), to resource constraints, to perceived threats to intellectual property, and other objections as well. During my 12-year tenure at USP, I have thought of such arguments against public monographs as my riddle of the sphinxone that ultimately will be solved, but that has, to date, thwarted most attempts to do so. USP has worked to refute these positions, but their currency can be maintained with unusual tenacity.
Convention News
USP Welcomes New Convention Members
These views are not without consequences for public health. For USPNF, approximately 50 percent of the book is either missing or needs updating, and similar observations could be made about other pharmacopeias of the world. Probably most of the medicines moving in global commerce lack good public monographs and reference materials. MC was designed to help correct these deficiencies through such measures as performance-based monographs, which provide tests for critical quality attributes and acceptance criteria but do not give step-by-step instructions, thereby allowing manufacturers and regulators greatly increased flexibility. So it is a good time to ask, roughly eight months since MCs public debut in July 2011: how is it doing? Well, it is doing very well and we are learning a lot. In a relatively short time, 15 monographs have been finalized and another 90 are in various stages in the pipeline, through a highly efficient public process. We are learning the pleasure of working with new and enthusiastic members of the 21st Expert Committee of the Council of Experts. Many of these experts come from manufacturers outside the United States who find strong value in pharmacopeial standards as a means of instilling consumer and practitioner confidence in medicines. We are learning how to create on our own a public monograph with reference materials rather than relying solely on manufacturer donations. And last but certainly not least, we are finding that work on MC lends itself to getting new monographs and updating existing ones in USPNF. These new opportunities have the capacity to protect all stakeholders, including manufacturers as well as practitioners, patients and regulatory agencies such as the U.S. Food and Drug Administration. This could happen by helping combat counterfeit or substandard medicines and by providing a common standard that follow-on or generic versions of a pioneer drug can follow. USP does not engage in market access decisions and works to protect confidential commercial and trade secret information. MC respects these commitments yet allows expansion of good drug monographs with reference materials both within and outside the United States. It thus synergizes with and supplements the already strong donor activity now ongoing in the United States. Does this sound too good to be true? Perhaps, but what a wonderful world it would be if USP could finally solve its riddle of the sphinx in ways that would advance not only its pharmacopeias but also those of other countries and regions, not to mention The International Pharmacopoeia of the World Health Organization. Global public health would surely be strengthened through such collaboration. I encourage readers to proceed to interviews with Drs. Tyle and Srinivasan to get a broader picture of what USP is doing to advance standards for foods and drugs in this very complicated world in which we live. u Organizations Representing Consumers and Public Interest Alzheimers Association American Autoimmune Related Diseases Association American Cancer Society American Childhood Cancer Organization American Heart Association Arthritis Foundation Bill and Melinda Gates Foundation Consumer Federation of America Consumers International Families USA Global Health Council International Alliance of Patients Organizations National Council on Patient Information and Education National Osteoporosis Foundation William J. Clinton Foundation Non-Governmental Standards-Setting Bodies Accreditation Council for Pharmacy Education Association for the Advancement of Medical Instrumentation ASTM International Clinical and Laboratory Standards Institute Pharmacy Compounding Accreditation Board URAC Academic Institutions Chicago State University College of Pharmacy NOVA Southeastern University College of Osteopathic Medicine Health Practitioner Professional and Scientific Associations American Society for Nutrition Manufacturer and Trade Associations China National Food Industry Association Governmental Bodies National Institute of Nutrition and Food Safety, Peoples Republic of China
w w w. u s p .o r g
USP Science
Q: Globalization and adulteration have received the attention of Congress, FDA and various watchdog groups. How can USP standards play a role as concerns about poor-quality medicines mount? A: There are various ways: up-to-date monographs and reference materials so the standards are public and verifiable; guidelines that assist with distribution in a global supply chain per General Chapters <1079> Good Storage and Shipping Practices and the new draft <1083> Good Distribution PracticesSupply Chain Integrity; workshops on hot topic areas such as supply chain integrity to get maximum industry and regulatory input into how USP should play in these areas; and spectral library work to potentially provide some immediate screening capabilities to assist in identifying items that should be removed from commerce. Q: As their role in law is far more limited, what do you see as the benefits of the Food Chemicals Codex (FCC) and the
USP Dietary Supplements Compendium (DSC), and are there evolutions taking place in these compendia as well? A: These compendia play a key role in establishing standards for food ingredients and dietary supplements. While voluntary (unless a dietary supplement is labeled USP), DSC monographs set a standard for quality that should be aspired to and allow independent parties to assess off-the-shelf materials against the USP standard of quality. While FCC is not an official compendium in the United States, it is recognized and is enforceable in more than 200 U.S. regulations and in other countries. USP is continuing to assess these compendia and, with dietary supplements, is considering broadening the scope to include traditional medicines marketed outside of the United States. With FCC, USP is evaluating ways to extend the reach and appeal of this compendium so manufacturers and others see it as an authoritative source for quality standards for food ingredients and will want to comply with these standards to demonstrate their materials are of the highest quality. u
Proposed General Chapter Addresses Subvisible Particulate Matter in Therapeutic Protein Injections
In response to issues initially raised by stakeholders from the biotechnology community, USP has developed a proposed new general chapter on particulate matter for biopharmaceutical injections. Particulate matter in injections consists of undissolved particles (other than gas bubbles) that are unintentionally present in a drug product. Proposed new General Chapter <787> Subvisible Particulate Matter in Therapeutic Protein Injections will be published in Pharmacopeial Forum 38(3) [MayJune 2012]. General Chapter <787> has been developed as an alternative to General Chapter <788> Particulate Matter in Injections. When General Chapter <788> was first developed for USPNF, it was designed to address the control of subvisible particles associated with small molecule injections. General Chapter <787> specifically addresses the unique requirements of therapeutic protein injections. However, either chapter can be used by manufacturers. General Chapter <788> outlines two procedures for quantifying particulate matter in small molecule drug injectionsa light obscuration method and a microscopic analysis method. While light obscuration is the preferred method when addressing biologics, the method as outlined in <788> poses some technical hurdles for biopharmaceuticals. For example, biologics are typically delivered as viscous, highly concentrated formulations that can trap air bubbles if they are not handled properly. This, in turn, can lead to inaccurate particulate matter readings. Another concern with many protein therapies has to do with factors that can lead to aggregation, breakage or agglomeration of a drug product, said Dr. Desmond Hunt, USP senior scientific liaison. The method outlined in General Chapter <788> allows for sonication to remove air bubbles. While sonication works well for small molecule injectables, it may be problematic for therapeutic proteins. Sonication can, through a number of mechanisms, lead to artificially high particulate matter readings. The hope is that this proposed new general chapter will help address some of these issues, especially as more biologics enter the therapeutic market, explained Dr. Hunt. u
w w w. u s p .o r g
USP Science
USP Proposes New Standards for Orally and Nasally Inhaled Medicines
For the first time, key players in the aerosols industry came together to discuss the challenges and limitations surrounding orally and nasally inhaled medicines during a workshop at USP headquarters in Rockville, Md., December 1213, 2011. With an emphasis on new and revised USP standards of interest to the aerosol community, the workshop also focused on technologies used to measure the quality of orally and nasally inhaled drug medications. These drugs are well accepted in the treatment of local nasal and lung diseases. USP is expanding its work in this area. USP has defined the taxonomy of the pharmaceutical dosage forms and classified the dosage forms based on the route of administration. The taxonomy has three tiers: the first is the route of drug administration (e.g., topical), the second is the type of the dosage form (e.g., tablet) and the third is the type of the drug release (e.g., immediate release). Aerosol products can be particularly difficult to set standards for as most of them do not technically become a drug until they are released from their containers. General Chapter <5> Inhalation and Nasal Drug ProductsGeneral Information and Product Quality Tests focuses on product quality tests such as identification, assay, and impurities for inhalation and nasal drug products. This is a new general chapter designed to be a companion to General Chapter <601> Product Performance TestsNasal and Inhalation Aerosols, Spray and Powders. This general chapter focuses on the product performance tests for these products and includes aerosol particle size determination and delivered-dose uniformity. Quality tests assess the integrity of the dosage form, whereas performance tests assess drug release and other attributes that relate to in vivo drug performance. Taken together, quality and performance tests ensure the identity, strength, quality and purity of the pharmaceutical dosage form. Dr. Anthony Hickey, a member of the USP General ChaptersDosage Forms Expert Committee, noted that these general chapters are not an attempt to replace or add to regulatory requirements, but rather aid in assessing the quality and performance of these products. Comments on the general chapters are currently under review by the Aerosols Subcommittee of the Expert Committee. u
Adulteration of Foods and Dietary Supplements Workshop Examines Current Vulnerabilities, the Role of Standards
To meet modern-day tastes and demands of consumers, the food and dietary supplement industries are accelerating global sourcing and manufacturing while utilizing increasingly innovative, functional and natural ingredients. As the complexity of supply chains grows with more distant sourcing of ingredients, so do the risks posed by adulteration. The extent of adulteration, the FDAs Daniel Fabricant discussed emergence of promising detecadulterated dietary supplements. tion techniques and the role that quality standards can play were among the areas of focus of a USP workshop held November 1617, 2011, in Rockville, Md. Discussions about the scope of adulteration in the dietary supplements arena kicked off the meeting, with Dr. Richard Ko of Herbal Synergy pointing to the various mechanisms of contamination that existincluding the addition of pharmaceuticals or other artificial ingredients, and substitution with different herbs or the same herb with inferior quality. He also provided real-life examples of the dire harm that adulterated supplements can pose to consumers, refuting the notion that this does not represent a serious public health problem. Dr. Amy Eichner of the U.S. Anti-Doping Agency impressed upon the workshops largely industry audience the consequences to athletes (and all consumers) of adulterated supplements, and why manufacturers in the audience need to care. Noting that these supplements are next to your good product on store shelves, Dr. Eichner said that adulterated supplements are not the fringe problem that many want to portray them as. Using the example of methylhexaneamine, which, although banned, is used in many sports supplements and often labeled as geranium oil, she said such adulteration is rampant. Dr. Daniel Fabricant, director of FDAs Division of Dietary Supplement Programs, further stressed the need for industry to take this problem seriously and join FDA in its work. Dr. Fabricant pointed to weight loss, sexual enhancement and body-building supplements as the most frequently adulterated products, and described increasing vigilance by the agency. Dr. Fabricant further spoke of the sometimes flagrant advertising of illegal ingredients and the need for responsible segments of industry to report bad players, noting that he saw anabolic steroid ingredients being promoted at a booth at a major industry trade show. Teeing up the issue of adulteration in food ingredients, Dr. Jonathan DeVries, chair of USPs Food Ingredients Intentional Adulterants Expert Panel, said that food adulteration is typically economically motivated. He offered an overview of current work and future topics to be tackled by the Expert Panel. The panel is seeking to prioritize new and revised monographs based on risk, with identified vulnerable ingredients including steviabased sweeteners, natural colors, infant formula ingredients, cocoa powder, sea salt and others. A current major initiative of the panel is one focused on skim milk powder. This ongoing USP-industry collaborative research project, through a USP advisory group, is evaluating the utility of different rapid nontargeted methods for discriminating authentic/pure skim milk powders from those that have been adulterated. The intention of this project is to create a tool box of rapid authentication methods, confirmatory methods, and new total protein methods along with reference materials to help prevent economically motivated adulteration of skim milk powder. Other speakers covered authenticity of food ingredients. New approaches for possible food ingredient standards in the Food Chemicals Codex (FCC) for juice concentratesin particular pomegranate juice concentratespices and natural colors were presented and discussed in detail. Quality standards to define the authenticity of food ingredients remain one of the ongoing challenges to the food industry and a major opportunity for FCC. The second day of the workshop was principally dedicated to the range of analytical approaches being employed to detect adulteration, including quantitative nuclear magnetic resonance, which may be used as a targeted approach for identifying known adulterants and non-targeted approach for unknown constituents; high-performance thin-layer chromatography, an automated technique that can be used qualitatively and quantitatively to detect adulterants; and chromatographic fingerprinting, which includes multiple techniques for authentication including microscopic, chemical and genetic. The second half of the day included two breakout sessions, one focused on dietary supplements and one focused on food ingredients, to discuss specific needs of these segments and recommendations for how USP can play a valuable role. Closing the workshop, USP summarized suggestions that emerged from the breakouts. For dietary supplements, these ranged from creating a general information chapter describing methods and tools to screen for adulterants, to various ways to enhance USPs monographs, to modifying USPs verification program to include screening for adulteration, particularly in sports supplements. For foods, ideas included partnering with other groups (e.g. trade associations, government agencies) to exchange information, to establishing a mechanism for sharing analytical methods within industry (e.g. using the skim milk powder project as a model), to holding recurring workshops on adulteration. Look to upcoming issues of The Standard for updates on this work. u
w w w. u s p .o r g
USP Science
Critical Quality Considerations for Probiotics and Other Microbial Food Cultures Offered in New Draft FCC Standards
With strong consumer interest in probioticsand new manufacturer innovations for incorporating these ingredients into a broader array of food productsnew standards to help ensure the quality of probiotic food ingredients were proposed in December 2011. The draft standards, which will be included in the Food Chemicals Codex (FCC), offer comprehensive information that is essential when utilizing probiotics as food ingredients, including testing to confirm the identity upon which probiotic product safety and health claims are based. Essential quality specifications such as identification and enumeration (microbe count), as well as intended uses in food, safety, regulatory status, and purity of probiotics and other microbial food cultures, are included in the new FCC Appendix, titled Microbial Food Cultures Including Probiotics. These specifications were proposed in the December FCC Forum. Proper identification with probiotics is important because safety studies are most often based on the genus/species or strain level, so it is critical that manufacturers know exactly which microorganism they are incorporating into their food product to ensure safety. Identification also is important in supporting purported health claims. Given that many different strains of microorganisms are cultured and have been tested and used in foods, any supporting studies for justifying health claims are at the specific strain level. For any claimed health benefit, manufacturers should be able to confirm that what they are using in a probiotic food product is indeed the strain tested. Enumeration is similarly important because any claimed health effects supported by study trial data would also be specific to the level of intake. Future standards development work at USP will potentially include individual monographs for specific probiotic strains, combined with more prescriptive details for identification and enumeration of the microorganisms of interest. USP will be hosting a workshop with the Institute of Food Technologists on May 910, 2012, to ascertain stakeholder needs to drive its future standards work. More information is available at www.usp.org/meetings-courses/ workshops. Other proposed standards in the FCC Forum included: Steviol GlycosidesNew standards for the popular natural stevia sweeteners. An FCC monograph for high-purity Rebaudioside A already exists, but the new Steviol Glycosides monograph covers a broader range of stevia-derived ingredients including mixtures of different steviol glycosides, which are being increasingly utilized in foods and beverages. An important component of the standard is a newly developed method capable of separating and measuring all nine glycosides, which has been difficult in the past. USP will have seven reference standards to support the monograph in the future. BenzoatesModernized standards for three benzoates to help address concerns about economically motivated adulteration. Widely used as preservatives, the three ingredientscalcium benzoate, potassium benzoate and sodium benzoatewere modernized with more specific identification tests and/or assay tests. In sourcing commercially available samples of calcium benzoate, USP laboratory staff was able to detect the adulteration of a commercial sample of allegedly pure calcium benzoate with calcium propionate by using the modernized monographs purity criteria. This is the goal of modernizing such monographsto create effective tools to deal with the threat of economically motivated adulteration by better specifying what should be present without testing for specific known adulterants. Infant Formula IngredientsContinuing a commitment to develop monographs for infant formula ingredients, standards were proposed for chromic chloride and sodium selenate anhydroussources of minerals chromium and selenium, respectively, used in baby formula. This follows the addition of a variety of infant formula ingredients in the FCC over the past several years. For these infant formula ingredients, no known standards exist in any other compendium. u
USP International
Global Public Health View, Flexible StandardsSetting Approach Drive New Compendium
In the following Q&A, Dr. Srini Srinivasan, USP executive vice president, international sites and standards, explains how the USP Medicines Compendium may benefit developing countries and advance harmonization.
Q: What does USP envision as the ultimate useand benefitof the USP Medicines Compendium?
Srini Srinivasan, Ph.D.
A: USP envisions, and is developing the USP Medicines Compendium (MC) as, a compendium for use by manufacturers and regulatory agencies around the globe. Its uniqueness lies in the fact that the performancebased monographs specified in the compendium, along with USP Reference Standards, allow greater flexibility that manufacturers might use to demonstrate conformance to public standards. Regulatory agencies in developing nations, many of which have resource constraints, can use these standards for determination of conformance to acceptable and safe public standards. This is further facilitated by the commitment of USP to ensure ongoing availability of its reference standards. USP hopes to provide public standards in MC for all those drugs and drug products that are legally marketed in developing nationseven those where no standards exist in any of the major pharmacopeias. The independent nature of the compendium supports manufacturers who are exporting to other developing nations by citing conformance to MC standards.
A: Although MC is focused on drugs approved outside the United States, the systems and processes used in the compendium derive their strength from USPs extensive history of setting standards for more than 190 years. The process by which documentary and reference standards are established is the same as that of USPNF. The Expert Committee responsible for MC is an integral part of the USP Council of Experts. MC generally relies on USPNF for non-monograph text such as general chapters. The reference procedures and impurity standards developed for MC have the potential to be introduced into USPNF. The procedure development processes developed for MC could find direct application in modernization efforts that are underway in USPNF. Many of the unique needs of MC have provided a new perspective that may better allow us to identify and correct gaps in USPNF monographs and general chapters. Ultimately, MC and USPNF each provide opportunities to inform and improve the other in synergistic ways. Q: In what direction do you hope to take MC? A: USP hopes that MC will provide credible public standards for chemical and biological medicines, and reference standards for drug substances as well as process and degradation impurities of concernall of which will contribute to protecting public health. Until this point, MC has focused on drug substances and some drug products available in the marketplace. In the near future, MC will be moving to incorporate excipients monographs and reference standards. USP also hopes that manufacturers that are exporting drug substances and products to other countries will adopt MC standards for their registration for market access purposes, thus providing regulatory agencies in those countries with a tool to combat the ever-increasing menace of counterfeit and substandard drugs. MCs purpose will have been achieved when more and more regulatory agencies around the globe accept these standards. Q: MC has been billed an experiment by USP. What is meant by that, and why is this experiment necessary? A: The term experiment was used initially because MC was the vehicle to test our concept of a performance-based monograph that includes tests, criteria-based procedures, acceptance criteria, a reference procedure (including reference materials suitable for use as comparison standards
Q: Why is it important for USP to develop standards at the international level? A: Major pharmacopeias in developed nations generally focus their attention on establishing public standards for drugs that treat diseases most relevant to their populations. In less-developed countries, due to resource constraints, national pharmacopeias have fallen behind in the establishment of public standards, even for drugs that are on the World Health Organizations Essential Medicines List. Further, when documentary standards are not supported by the ready availability of reference standards for conformance assessment, regulatory control of spurious and counterfeit drugs becomes a difficult task. Due to the global nature of MC, the focus is on establishing public documentary and reference standards for chemical and biological medicines that are relevant to diseases prevalent in all countries, with a priority on those under-served nations. Q: How does MC fit in with USPs domestic activities (specifically USPNF)? Are there synergies among the compendia?
w w w. u s p .o r g
USP International
in MC tests and assays) and acceptable procedures. The performance-based monograph differs from the traditional USP approach, which relies on a sponsor-supplied analytical method with validation data. The feasibility of developing a reference procedure that is independent of the source of the drug substance tested needed to be assessed in the laboratory for various articles. The feasibility studies established that reference procedure development is indeed viable and found to work satisfactorily and acceptable to the Expert Committee that authorizes MC monographs for final publication. Q: Is there anything youve learned since launching MC that youve been surprised by? A: Indeed, we have learned a lot during this process. Whenever you have the opportunity to consider all the underlying assumptions of the rules and processes of a pharmacopeia that has grown and changed dramatically over the past 190 years, there are bound to be surprises. We have found that we are working with a completely different group of users than with USPNF. These users have not had the benefit of years of experience to fall back upon, and therefore, we have found that the educational needs are much greater for MC than for USPNF. We have found that starting an Expert Committee in another country was no more difficult than forming a new Expert Committee in the United States. However, we discovered that certain policies relating to
the impurities, performance standards for the oral solid dosage forms and the details of the performance-based monographs have needed a great deal of attention and time for development. Q: How does MC support not only USPNF but also the other pharmacopeias of the world? A: The performance-based monographs that characterize MC may, in our opinion, provide the most effective means to achieve global harmonization. MC standards are freely available to all pharmacopeias of the world for consideration or incorporation as appropriate. MC is also dedicated to creating reference standards for process impurities and degradation products for every drug substance monograph. These standards have parallels in pharmacopeias that do not have the infrastructure or resources to create these standards. These reference standards create the basis for global comparisons of drug substances. The monographs provide modern methods for regulatory testing that are designed and intended to be broadly applicable to a wide variety of synthetic processes. As we are in the process of continually revising existing USPNF monographs, the MC monograph approach is under consideration for use in USPNF. Since MC is a web-based publication free for all users including regulatory agencies and other pharmacopeias, USP will encourage other pharmacopeias to consider adopting MC monographs into their national pharmacopeias. u
10
Global Quality Standards for Biologics and Supply Chain Management the Focus of Mumbai Meeting
Indias role as a leading figure in global pharmaceutical manufacturing brought together nearly 400 regulators, manufacturers and other stakeholders in global public health at the 11th Indian Pharmacopoeia Commission (IPC)-USP Science & Standards Symposium on February 2223, 2012, in Mumbai. The symposium addressed ways that science and quality standards can help ensure good quality medicines in India and throughout the world. The symposium focused on two important areas for Indias pharmaceutical sectorglobal quality standards for biologic medicines and supply chain management. Also highlighted were efforts related to the USP Medicines Compendium (MC) USPs free, online compendium comprising quality standards for medicines moving in international commerce. Indian manufacturers play in todays biologics market. Other speakers on the topic of biologics included Dr. Ivana Knezevic of the World Health Organization (WHO) quality and safety of biologicals group, presenting on WHOs approaches to biologic and biosimilar medicines, and Dr. Nora Dellepiane, who addressed the vaccine prequalification program of WHO. In addition to vaccines, meeting topics covered therapeutic proteins, another important class of drugs for Indias growing biologics manufacturing sector; strategic perspectives on biotechnology products in developing countries; the role of bioassays in biosimilarity; and the replacement of animal studies for potency testing of human vaccines. Speakers represented such organizations as the National Institute for Biological Standards and Control (United Kingdom), the Central Research Institute (Kasauli), and the Serum Institute of India (Pune) as well as Indian manufacturers, Biocon and Biological Evans.
The meeting was part of a In a presentation track dedicated continuing USP effort with the to supply chain management, government of India and the speakers included USP Expert IPC to promote access to good Committee members currently quality medicinesnot only involved in the development of those being exported but also USP General Chapter <1083> From left: Dr. Satya Dash, Association of Biotechnology Led those intended for the people of Good Distribution Practices Enterprises; Dr. Williams, USP; Dr. B. Suresh, IPC. India. Coincident with the 11th Supply Chain Integrity. This is Symposium, USP and IPC also a first-of-its-kind USP general hosted additional meetings, including joint conclaves between chapter in USPNF, designed to encourage comprehensive public the two pharmacopeial bodies and meetings of the Expert standards on supply chain issues across the pharmaceutical industry. Committee responsible for MC. Additional symposium session topics related to supply chains Co-sponsors for the symposium were the Association of were cold chain management; pharmacopeial advances in Biotechnology Led Enterprises, the Bulk Drug Manufacturers packaging standards; storage and shipping of pharmaceuticals; Association, the Indian Drug Manufacturers Association, the and synergies between supply chain management and risk Indian Pharmaceutical Association and the Organization of management. Speakers presented on behalf of various organizaPharmaceutical Producers of India. tions including Pfizer, Dr. Reddys Laboratories, Bio Bridge, the U.S. Food and Drug Administration (India) and The event opened with a keynote address delivered by Mr. the Pharmaceuticals Export Promotion Council of India Pankaj Patel, chief executive officer of Zydus Cadila, and a guest (PHARMEXCIL). Established in 2004, PHARMEXCIL has lecture by Mr. K.V. Subramaniam, chief executive officer of played an important role in addressing trade- and exportReliance Life Sciencesa part of Reliance Group, one of Indias related issues that specifically impact the Indian pharmaceutical largest private sector enterprises. Mr. Subramaniam discussed industry, including the development of barcode technologies biosimilar productsbiologic drugs manufactured to be similar to help protect pharmaceutical exports from India against the in therapeutic impact to innovator productsand the role that threat of adulteration and counterfeiting. u
w w w. u s p .o r g
11
USP International
The summit began with a general introduction of each country or regions pharmacopeia, which included overviews on organizational structures, missions, descriptions of standards and their relationships to regulations. Roundtable exchanges among participants on topics of interest included discussions on standards for biologics, Traditional Chinese Medicines, homeopathic medicines and herbal mixtures; green practices to support pharmacopeial standards; strategic approaches of The International Pharmacopoeia relative to other pharmacopeias; harmonization benefits and challenges; interchangeability of analytical instrument methods; and monograph updating and development. Additionally, Dr. Williams provided an overview of the USP Medicines Compendium USPs free, online compendium comprising quality standards for medicines moving in international commerce. Mr. Wang Ping, deputy secretary general of ChP, discussed a ChP proposal to develop an index of world pharmacopeial standards for drug substances and products. Follow-on actions were considered, which included an offer by ChP to host the next summit in China in conjunction with the biannual scientific symposium hosted by USP and ChP in late 2012. At the end of the summit, a majority of the participants reached an agreement to continue pursuing global pharmacopeial collaborations through the promotion of safe medication and quality standards, establishing the Global Summit of the Pharmacopeias as a platform for continued dialogues and effective collaborations among pharmacopeias. The second summit is planned for September 2012 in Xian. u
12
w w w. u s p .o r g
13
USP International
USP-Africa Center Continued from front cover.
A 2009 report by the U.S. Agency for International Development (USAID) and USP pointed to the ubiquity of poor-quality medicines. In it, roughly one-third of the selected antimalarials in three African nations tested was found to be substandard. Such medicines result in severe patient outcomes including death, and additionally contribute to the growth of drug-resistant disease parasites. CePAT is the outcome of a pilot Technical Assistance Program (TAP) that USP launched last year in six countries. Under the program, USP provided trainings as well as its documentary and reference standards for free or at reduced pricing. During a regional training session in Ghana with the national laboratories of five participating African countries, it became clear that there was a need for a more permanent presence that could deliver training on-demand, tailored to local needs. Rather than having USP employees from the United States conduct isolated courses on specific topics, we believe a more sustainable approach is to train local experts, fostering a knowledge base and thus equipping African chemists to further train others to create a lasting regional solution, explained Mr. Hendrix. USP has worked in specific African countries through grants from USAID (the Promoting the Quality of Medicines, or PQM, program and predecessor programs) for decades, and the center will complement and build upon this work. This will mark a significant scaling-up of independent USP activity in the region. While the USAID grants have allowed USP to make tremendous strides in advancing the quality of antimalarial, antituberculosis and antiretroviral medicines, CePAT will not be limited to medicines treating those diseases but will focus on stimulating systemic changes that can be sustained locally. One of the key challenges the development community faces is that most programs are based on vertical fundingmeaning it is disease-specific. With CePAT, we intend to transcend this sort of model, strengthening the infrastructure of countries as a whole so our work will impact all medicines, noted Dr. Patrick Lukulay, USP vice president of global health impact programs. USPs $1.5 million pledge will supplement funding from outside donors to cover construction, instrumentation and staffing costs, and to subsidize local use of the center for the first three years. Based on external funding obtained and other relevant factors, CePAT will be subject to final Board approval. USP expects the center to become self-sustaining after three years through the variety of services it will provide to local manufacturers, regulators and others. These are envisioned to include trainings on topics such as quality control and current Good Manufacturing Practices; quality control testing services for donor agencies, procurement organizations or local manufacturers; and consulting services on supply chain integrity and laboratory design, among other offerings.
Africa Trip
USP leadership, including Dr. Roger L. Williams, chief executive officer; Mr. Hendrix; Dr. Srini Srinivasan, executive vice president, international science and standards; Ms. Angela Long, senior vice president, global alliances and organizational affairs; and Dr. Lukulay, laid local groundwork for the center during a weeklong trip to Africa in December 2011. The group visited three countriesGhana, South Africa and Ethiopiameeting with government officials and other key stakeholders to introduce the concept, seek input and explore possible partnerships. Across these meetings, the idea was greeted with much enthusiasm. The trip commenced in Ghana, where the USP team was welcomed by a tribal delegation in a ceremony full of tradition. This included acrobatics, dancing, fire-eating and the presentation of kente cloth. USP donated five laptops to be used in local schools. Following this ceremony, the group took time to explore some of the countrys history, including a visit to the infamous Elmina Castle and its Door of No Return. Established in 1482, this was a major trading outpost in the Atlantic Slave Trade for roughly three centuries. While in Ghana, the group met with key officials in the country, including The Honorable Joseph Yieleh-Chireh, former minister of health; Major General Smith, minister of defense; and Dr. Stephen Opuni, chief executive officer of the Ghana Food and Drugs Board. From there, the group traveled to South Africa for another series of meetings, including the Medicine Control Council. They ended the trip in Ethiopia, where they met with government officials including Minister of Health Kebede Worku and a group from the Food, Medicine and Health Care Administration and Control Authority. According to Ms. Long, the trip enabled face-to-face interactions that assist in building trust, friendship and relationships that will open the doors to meaningful collaborations. The establishment of CePAT represents the next phase in USPs long and rich history of advancing public health, and we are very pleased to take part in what we believe will be a lasting contribution to the region. u
14
PQM Program
As a result of this trip, SFDA, Yunnan During visits to health facilities and FDA, Yunnan Food and Drug Quality pharmacies, they gathered information Laboratory, WHO and PQM developed on malaria incidence and control efa plan to conduct a base-line survey forts at the county level, the availability of antimalarials. It clearly defines Dr. Phanouvong conducts a visual inspection in a local pharmacy. of antimalarial medicines and the chalroles and responsibilities for each lenges the local health and authorities key stakeholder and will produce a are facing. The team also tried to learn if there were concerns valid surveythe first step in establishing an improved MQM about medicines quality and, if so, what should be done about program in Yunnan province. u
w w w. u s p .o r g
15
Inside USP
Global Philanthropic Health Initiatives Strengthened with New USP Vice President of Development
USP welcomed Ms. Reema Jweied-Guegel as vice president of development in January 2012. In this role, Ms. Jweied-Guegel is leading the newly formed development department, which is tasked with making USPs standards broadly available to all countries and obtaining philanthropic funding to support current and future global health initiatives. As USP develops its philanthropic efforts, a leader like Reema who possesses such extensive global experience was a natural fit, said Mr. Brian Hendrix, executive vice president and chief operating officer at USP. She will be building on the strong foundation USP has established with programs that help combat substandard and counterfeit medicines in developing countries and also seek philanthropic funding to help USP increase its global reach and impact. I welcome Reema to USP and I look forward to her expertise guiding USPs charitable outreach. Ms. Jweied-Guegel has more than 17 years of experience in the nonprofit sector. Prior to joining USP, Ms. Jweied-Guegel served for eight years as the senior vice president at the U.S.-Jordan Business Alliance, an organization founded under the auspices of His Majesty King Abdullah II. There, she worked to further the economic relationship between the United States and Jordan through outreach to companies in key sectors. Ms. Jweied-Guegel has also served as a senior advisor to the Business Council for International Understanding as well as the executive director of marketing and strategic development at the National U.S.-Arab Chamber of Commerce. Ms. Jweied-Guegel received her master of business administration in marketing from George Washington University, where she was inducted into the international honor society Beta Gamma Sigma. She is a graduate of the 2003 Leadership America class and currently sits on the Steering Committee for the Arab American Institute Foundations Khalil Gibran Spirit of Humanity Awards. u
Headquarters 12601 Twinbrook Parkway Rockville, Maryland 20852 U.S.A. +1-301-881-0666 1-800-227-8772 (U.S. and Canada) 00-800-4875-5555 (Select Europe) Europe/Middle East/Africa Mnchensteinerstrasse 41 CH-4052 Basel, Switzerland +41 (0)61 316 30 10 USPIndia Private Limited IKP Knowledge Park Turkapally Village Genome Valley Shameerpet, Ranga Reddy District, Hyderabad 500 078, A.P., India +91-40-2348-0088 USPChina Building 11, Lane 67, Libing Road Zhangjiang Hi-Tech Park 201203 Shanghai China +86-21-51370600 USPBrazil Avenida Ceci, 1600 - Tambor Barueri-SP 06460-120 Brazil +55-11-3245-6400
www.usp.org
EA390NL _ 2012-03
Copyright 2012 The United States Pharmacopeial Convention. All Rights Reserved.